Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
$1.98
-6.2%		$0.98
$0.62
▼
$12.43
$12.97M1.61262,825 shs511,439 shs
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
$0.57
-5.9%		$0.89
$0.57
▼
$19.21
$1.98M3.662.12 million shs226,655 shs
Immuron stock logo
IMRN
Immuron
$1.12
+4.8%		$1.13
$0.68
▼
$2.39
$9.05M1.16112,275 shs11,756 shs
OSR Holdings, Inc. stock logo
OSRH
OSR
$0.30
-11.5%		$0.36
$0.08
▼
$0.91
$10.49M0.566.61 million shs676,707 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
+22.67%+50.71%+201.43%+97.20%-82.12%
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
-4.24%-5.66%-11.10%-70.17%-96.75%
Immuron stock logo
IMRN
Immuron
-3.60%-6.14%-1.83%-21.61%-40.88%
OSR Holdings, Inc. stock logo
OSRH
OSR
+22.73%+189.70%-24.67%-19.78%-56.54%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
$1.98
-6.2%		$0.98
$0.62
▼
$12.43
$12.97M1.61262,825 shs511,439 shs
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
$0.57
-5.9%		$0.89
$0.57
▼
$19.21
$1.98M3.662.12 million shs226,655 shs
Immuron stock logo
IMRN
Immuron
$1.12
+4.8%		$1.13
$0.68
▼
$2.39
$9.05M1.16112,275 shs11,756 shs
OSR Holdings, Inc. stock logo
OSRH
OSR
$0.30
-11.5%		$0.36
$0.08
▼
$0.91
$10.49M0.566.61 million shs676,707 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
+22.67%+50.71%+201.43%+97.20%-82.12%
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
-4.24%-5.66%-11.10%-70.17%-96.75%
Immuron stock logo
IMRN
Immuron
-3.60%-6.14%-1.83%-21.61%-40.88%
OSR Holdings, Inc. stock logo
OSRH
OSR
+22.73%+189.70%-24.67%-19.78%-56.54%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
1.80
Reduce$73.003,586.87% Upside
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
1.50
Reduce$150.0026,215.79% Upside
Immuron stock logo
IMRN
Immuron
1.00
SellN/AN/A
OSR Holdings, Inc. stock logo
OSRH
OSR
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest GOVX, OSRH, FBLG, and IMRN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/20/2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (E+) ➝ Sell (E)
8/4/2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$8.00 ➝ $6.00
8/4/2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeUnderperform
7/24/2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (E+)
7/17/2026
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/7/2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (E+) ➝ Sell (E)
6/24/2026
Immuron stock logo
IMRN
Immuron
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
OSR Holdings, Inc. stock logo
OSRH
OSR
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/17/2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (E+)
(Data available from 9/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/AN/AN/AN/A$0.70 per shareN/A
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
N/AN/AN/AN/A$0.51 per shareN/A
Immuron stock logo
IMRN
Immuron
$5.47M1.65N/AN/A$0.93 per share1.21
OSR Holdings, Inc. stock logo
OSRH
OSR
$1.81M5.80N/AN/A$3.56 per share0.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-$18.65M-$5.19N/AN/AN/AN/A-536.78%-225.12%10/30/2026 (Estimated)
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
-$21.47M-$11.34N/AN/AN/AN/A-743.64%-394.74%11/12/2026 (Estimated)
Immuron stock logo
IMRN
Immuron
-$2.72MN/AN/AN/AN/AN/AN/AN/AN/A
OSR Holdings, Inc. stock logo
OSRH
OSR
-$27.06M-$0.37N/AN/AN/A-593.15%-8.36%-6.24%N/A

Latest GOVX, OSRH, FBLG, and IMRN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q4 2026
Immuron stock logo
IMRN
Immuron
N/A-$0.09N/A-$0.0850N/A$1.27 million
8/14/2026Q2 2026
OSR Holdings, Inc. stock logo
OSRH
OSR
N/A-$0.02N/A-$0.02N/A$0.32 million
7/31/2026Q2 2026
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
-$0.93-$0.66+$0.27-$0.66N/AN/A
7/27/2026Q2 2026
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
-$2.16-$0.97+$1.19-$0.97N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/AN/AN/AN/AN/A
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
N/AN/AN/AN/AN/A
Immuron stock logo
IMRN
Immuron
N/AN/AN/AN/AN/A
OSR Holdings, Inc. stock logo
OSRH
OSR
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/A
2.64
2.64
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
N/A
1.54
1.54
Immuron stock logo
IMRN
Immuron
N/A
7.17
6.83
OSR Holdings, Inc. stock logo
OSRH
OSR
N/A
0.18
0.14

Institutional Ownership

CompanyInstitutional Ownership
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
N/A
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
6.09%
Immuron stock logo
IMRN
Immuron
0.12%
OSR Holdings, Inc. stock logo
OSRH
OSR
55.30%

Insider Ownership

CompanyInsider Ownership
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
7.30%
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
0.69%
Immuron stock logo
IMRN
Immuron
7.01%
OSR Holdings, Inc. stock logo
OSRH
OSR
36.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
FibroBiologics Inc. stock logo
FBLG
FibroBiologics
106.66 million6.17 millionN/A
GeoVax Labs Inc. stock logo
GOVX
GeoVax Labs
103.47 million3.45 millionNot Optionable
Immuron stock logo
IMRN
Immuron
N/A8.07 million7.51 millionNot Optionable
OSR Holdings, Inc. stock logo
OSRH
OSR
N/A35.12 million22.16 millionN/A

Recent News About These Companies

Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc.
August 27, 2026  |  accessnewswire.comA
OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission
August 21, 2026  |  accessnewswire.comA
OSR Health, Inc.: OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal
August 20, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69356686-osr-health-inc-osr-health-receives-nasdaq-staff-delisting-determination-and-intends-to-request-hearings-panel-appeal-200.htm
OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal
August 19, 2026  |  accessnewswire.comA
OSR Health, Inc.: OSR Health Sees Global Shareholder Momentum at Critical Inflection Point
August 19, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69351809-osr-health-inc-osr-health-sees-global-shareholder-momentum-at-critical-inflection-point-200.htm
OSR Health Sees Global Shareholder Momentum at Critical Inflection Point
August 19, 2026  |  accessnewswire.comA
OSR Holdings Stock Price History
August 18, 2026  |  investing.comhttps://www.investing.com/equities/bellevue-life-sciences-acq-historical-data
OSR Health Inc (OSRH) Stock Price, Quote, News & History
August 11, 2026  |  benzinga.comhttps://www.benzinga.com/quote/OSRH
OSR Health, Inc.: OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development
August 11, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69277330-osr-health-inc-osr-health-ceo-reaffirms-confidence-and-highlights-subsidiary-business-development-200.htm
OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development
August 11, 2026  |  accessnewswire.comA
OSR Health Inc.
August 9, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/osrh/financials/cash-flow
OSRH OSR Health, Inc.
August 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/symbol/OSRH/sec-filings
OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program
August 7, 2026  |  accessnewswire.comA
Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform
August 3, 2026  |  accessnewswire.comA
OSR Health, Inc.: OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment
August 1, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-07/69186987-osr-health-inc-osr-health-secures-nasdaq-communication-loyalty-cvr-program-will-not-trigger-a-price-adjustment-200.htm
OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment
July 31, 2026  |  accessnewswire.comA
OSR Health, A Message From the CEO
July 13, 2026  |  accessnewswire.comA
OSR Health Earnings Estimates, EPS & Revenue | NASDAQ:OSRH
July 6, 2026  |  benzinga.comhttps://www.benzinga.com/quote/OSRH/earnings
CORRECTION FROM SOURCE: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
July 2, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/correction-source-emerging-growth-research-170500642.html
Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target
July 2, 2026  |  accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

FibroBiologics stock logo

FibroBiologics NASDAQ:FBLG

$1.98 -0.13 (-6.16%)
As of 03:11 PM Eastern
This is a fair market value price provided by Massive. Learn more.

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

GeoVax Labs stock logo

GeoVax Labs NASDAQ:GOVX

$0.57 -0.04 (-5.88%)
As of 03:10 PM Eastern
This is a fair market value price provided by Massive. Learn more.

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.

Immuron stock logo

Immuron NASDAQ:IMRN

$1.12 +0.05 (+4.77%)
As of 03:05 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.

OSR stock logo

OSR NASDAQ:OSRH

$0.30 -0.04 (-11.53%)
As of 02:38 PM Eastern

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas